This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About HilleVax Stock (NASDAQ:HLVX) Get HilleVax alerts:Sign Up Key Stats Today's Range$2.09▼$2.0950-Day Range$2.06▼$2.1252-Week Range$1.77▼$2.17VolumeN/AAverage Volume532,880 shsMarket Capitalization$104.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview HilleVax, Inc. is a clinical-stage biotechnology company focused on the development of broadly protective vaccines against enteric pathogens. The company leverages a proprietary O-antigen platform to generate multivalent vaccine candidates designed to elicit immunity to multiple strains of enterotoxigenic Escherichia coli (ETEC), Shigella and Vibrio cholerae. HilleVax’s lead candidate, HIL-214, is currently advancing through Phase I clinical trials to assess safety and immunogenicity in adult populations. Founded as a spin-out from Hilleman Laboratories with support from philanthropic and industry partners, HilleVax has built a pipeline of product candidates aimed at addressing diseases that disproportionately impact low- and middle-income countries as well as travelers. In addition to HIL-214, the company is developing second-generation candidates for shigellosis and cholera, each leveraging the same O-antigen conjugation technology to streamline manufacturing and broaden strain coverage. Strategic collaborations and research partnerships underpin the company’s efforts to optimize vaccine formulations and accelerate global development. Headquartered in Cambridge, Massachusetts, HilleVax conducts research and development activities in the United States while engaging with international public health agencies, academic institutions and non-governmental organizations to support clinical trial execution and eventual vaccine deployment. Led by CEO William J. Harty, the management team brings extensive experience in vaccine development, regulatory affairs and global commercialization planning. As a publicly listed entity on NASDAQ under the symbol HLVX, HilleVax is positioning itself to address unmet medical needs in enteric disease prevention on a global scale.AI Generated. May Contain Errors. Read More Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLVX Stock News HeadlinesHILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVXAugust 19, 2025 | globenewswire.comHilleVax, Inc. Reports Q2 2025 Financial ResultsAugust 15, 2025 | tipranks.com25-Cent Gold Explorer Set to Drill Top Canadian Mineral BeltWith gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign on an already large gold discovery in one of Canada's most mining-friendly jurisdictions. The company controls a multi-million-ounce gold system with multiple high-priority targets and a strong treasury to support aggressive exploration. Multiple catalysts are stacked for 2H 2026 and beyond - at a market cap that still reflects very little of the potential.June 24 at 1:00 AM | Resource Stock Digest (Ad)HilleVax Announces Merger Agreement with XOMAAugust 14, 2025 | theglobeandmail.comShareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 8, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)August 7, 2025 | prnewswire.comHilleVax Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comHILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVXAugust 5, 2025 | businesswire.comSee More Headlines HLVX Stock Analysis - Frequently Asked Questions How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) announced its earnings results on Wednesday, August, 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an initial public offering on Thursday, April 28th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share. What other stocks do shareholders of HilleVax own? Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/06/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 HLVX's financial health is in the Green zone, according to TradeSmith. HLVX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HLVX CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$147.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.29% Return on Assets-28.50% Debt Debt-to-Equity RatioN/A Current Ratio26.39 Quick Ratio26.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.67Miscellaneous Outstanding Shares50,140,000Free Float37,656,000Market Cap$104.79 million OptionableNot Optionable Beta0.77 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:HLVX) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | Sponsored25-Cent Gold Explorer Set to Drill Top Canadian Mineral BeltWith gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign o...Resource Stock Digest | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredBig Oil knew about this for 50 yearsIn the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil ...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredViral “AI Black Paper”A former CIA advisor is warning that an AI bubble collapse could trigger an 80 percent drop in the Dow as soon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
